Johnson & Johnson and its fellow SGLT2 drugmakers are all working to show benefits for patients with kidney disease. But in that population, J&J is touting data its rivals don’t have. More: ADA: J&J's struggling Invokana slashes heart, kidney
read moreTuesday was a twofer for Merck, which notched two new FDA approvals for blockbuster Keytruda in previously untreated head and neck cancer patients. More: Merck's Keytruda, passing Opdivo, bags double head and neck cancer OK Source: fierce
read moreBoehringer Ingelheim and Eli Lilly have already shown that Tradjenta doesn’t hurt patients’ hearts. But the pair is back with even more supporting evidence that it hopes will bolster the drug’s profile in a competitive field. More: ADA: Lilly, Boehringer's
read moreAbbVie already has blockbuster hopes for newly approved immunology drug Skyrizi as its old top-seller Humira nears the end of its megablockbuster run. Now, it has rolled out results to back longer-term use of the new IL-23 inhibitor in plaque
read moreThe SMC published advice accepting five new medicines. More: Imfinzi, Opdivo among latest SMC decisions Source: News
read moreA single 14-day course of PRV-031 was found to significantly delayed the onset and diagnosis of clinical type I diabetes. More: Provention’s PRV-031 found to delay type II diabetes by two years Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals